0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 41-60 of 77 Articles
JAMA Neurology Clinical Challenge 
Megan G. Hofmeister, MD; Angela Dao, BA; April M. Young, PhD, MPH

An 80-year-old man presented to the hospital with new-onset slurred speech and left-sided facial droop. Magnetic resonance imaging scans of the head were visually interpreted to show an acute infarct involving the posterior right frontal lobe. What is your diagnosis?

Comment & Response 
Graham Martin, ED, FRCS, MRCP, FRACS, Dip Occup Health

To the Editor In the article by Mez et al,1 half (5 of 10) of the lesions in the thin section specimen (panel B in the article’s Figure) stained for AT8, are in the sulcal depths of gyri. Is this characteristic of chronic traumatic encephalopathy?

Editorial 
Nathan P. Staff, MD, PhD

Amyotrophic lateral sclerosis (ALS) is a devastating fatal paralytic neurodegenerative disorder that is driven by complex and insufficiently understood pathophysiologic mechanisms. In the clinic, ALS is rarely difficult for the neurologist to recognize; yet considerable interpatient variability exists for what is considered to be a singular disorder. Variability ...

Editorial 
Erin E. Longbrake, MD, PhD; David A Hafler, MD

The clinical heterogeneity associated with progression to disability remains one of the mysteries surrounding multiple sclerosis (MS) and can be a source of consternation to patients and physicians alike. Patients who appear neurologically comparable at diagnosis often have widely divergent disease courses: some progress rapidly and require assistance ...

Original Investigation 
Noriko Isobe, MD, PhD; Anisha Keshavan, BSc; Pierre-Antoine Gourraud, PhD, MPH; Alyssa H. Zhu, MSc; Esha Datta, MSc; Regina Schlaeger, MD; Stacy J. Caillier, BSc; Adam Santaniello, BSc; Antoine Lizée, MSc; Daniel S. Himmelstein, BSc; Sergio E. Baranzini, PhD; Jill Hollenbach, PhD, MPH; Bruce A. C. Cree, MD, PhD, MAS; Stephen L. Hauser, MD; Jorge R. Oksenberg, PhD; Roland G. Henry, PhD
Includes: Supplemental Content

Importance  Although multiple HLA alleles associated with multiple sclerosis (MS) risk have been identified, genotype-phenotype studies in the HLA region remain scarce and inconclusive.

Objectives  To investigate whether MS risk-associated HLA alleles also affect disease phenotypes.

Design, Setting, and Participants  A cross-sectional, case-control study comprising ...

Editorial: Linking Genotype to Clinical Phenotype in Multiple Sclerosis; Erin E. Longbrake, MD, PhD; David A Hafler, MD
Original Investigation 
Isabella Fogh, PhD; Kuang Lin, PhD; Cinzia Tiloca, PhD; James Rooney, MD; Cinzia Gellera, PhD; Frank P. Diekstra, MD; Antonia Ratti, PhD; Aleksey Shatunov, PhD; Michael A. van Es, MD, PhD; Petroula Proitsi, PhD; Ashley Jones, PhD; William Sproviero, PhD; Adriano Chiò, MD; Russell Lewis McLaughlin, PhD; Gianni Sorarù, MD, PhD; Lucia Corrado, PhD; Daniel Stahl, PhD; Roberto Del Bo, PhD; Cristina Cereda, PhD; Barbara Castellotti, PhD; Jonathan D. Glass, MD; Steven Newhouse, PhD; Richard Dobson, PhD; Bradley N. Smith, PhD; Simon Topp, MSc; Wouter van Rheenen, MD; Vincent Meininger, MD, PhD; Judith Melki, MD, PhD; Karen E. Morrison, MD; Pamela J. Shaw, MD; P. Nigel Leigh, MD, PhD; Peter M. Andersen, MD, DMSc; Giacomo P. Comi, MD; Nicola Ticozzi, MD; Letizia Mazzini, MD; Sandra D’Alfonso, PhD; Bryan J. Traynor, MD; Philip Van Damme, MD, PhD; Wim Robberecht, MD, PhD; Robert H. Brown, MD, DPhil; John E. Landers, PhD; Orla Hardiman, MD, FRCPI; Cathryn M. Lewis, PhD; Leonard H. van den Berg, MD, PhD; Christopher E. Shaw, MD; Jan H. Veldink, MD, PhD; Vincenzo Silani, MD; Ammar Al-Chalabi, PhD, FRCP; John Powell, PhD
Includes: Supplemental Content

Importance  Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset neurodegenerative disorder with a poor prognosis and a median survival of 3 years. However, a significant proportion of patients survive more than 10 years from symptom onset.

Objective  To identify gene variants influencing survival in ALS.

Design, ...

Editorial: Variability in Amyotrophic Lateral Sclerosis; Nathan P. Staff, MD, PhD
Images in Neurology 
Marina Herwerth, MD; Sascha Prothmann, MD; Kornelia Kreiser, MD; Bernhard Hemmer, MD; Markus Ploner, MD

This case report describes a woman in her early 40s with fluctuating neck pain in whom imaging revealed spontaneous cerebrospinal fluid leakage with engorgement of venous plexus.

Comment & Response 
Terry Ellis, PhD, PT, NCS; Linda Tickle-Degnen, PhD, OTR/L; Marie Saint-Hilaire, MD, FRCPC

To the Editor It is with great concern that we comment on the randomized clinical trial by Clarke et al1 published in JAMA Neurology. The study objective was to perform a large pragmatic randomized clinical trial to evaluate the clinical effectiveness of individualized physiotherapy (PT) and ...

Comment & Response 
Nienke M. de Vries, PhD; Ingrid H. Sturkenboom, PhD; Bastiaan R. Bloem, MD, PhD

To the Editor There is increasing evidence for the effectiveness of nonpharmacological interventions in Parkinson disease (PD).1,2 In contrast, the PD REHAB Trial suggested that physiotherapy (PT) combined with occupational therapy (OT) offers no meaningful improvements in activities of daily living or quality of life ...

Comment & Response 
Régis Gemerasca Mestriner, PT, PhD

To the Editor I read with interest the article by Clarke et al.1 They provide an interesting randomized clinical trial showing physiotherapy (PT) and occupational therapy (OT) are not associated with immediate or medium-term clinically significant improvements in activities of daily living or quality of life in ...

Comment & Response 
Carl E. Clarke, MD; Marion F. Walker, PhD; Catherine M. Sackley, PhD

In Reply On behalf of the PD REHAB Collaborative Group, we are pleased that the PD REHAB Trial1 has prompted debate. The issues raised are common to the 3 letters24 and all were covered in the original article.1

Childhood stroke studies often cite differences in risk factors between adult and pediatric patients, namely that traditional adult stroke risk factors, such as hypertension and hyperglycemia, are not common causes of childhood stroke.14 In a study2 of 83 children from the United Kingdom, only ...

Editorial 
Stephen W. Clark, MD, PhD

The world’s population is aging and rapidly increasing; it is estimated to reach 9.4 billion in 2050, with 1.5 billion people older than 65 years.1 In parallel to an aging population, cancer incidence is expected to rise, and in 2035 it is estimated that 70% of diagnosed ...

Original Investigation 
Chad G. Rusthoven, MD; Matthew Koshy, MD; David J. Sher, MD; Douglas E. Ney, MD; Laurie E. Gaspar, MD; Bernard L. Jones, PhD; Sana D. Karam, MD, PhD; Arya Amini, MD; D. Ryan Ormond, MD; A. Samy Youssef, MD, PhD; Brian D. Kavanagh, MD
Includes: Supplemental Content

Importance  The optimal management for elderly patients with glioblastoma (GBM) is controversial. Following maximal safe resection or biopsy, accepted treatment paradigms for elderly patients with GBM include combined-modality therapy (CMT) with both radiotherapy (RT) and chemotherapy (CT), RT alone, and CT alone.

Objective  To evaluate the ...

Editorial: The Age Factor in the Treatment of Glioblastoma; Stephen W. Clark, MD, PhD
Original Investigation 
Kimberly N. Grelli, MD; Melissa C. Gindville, MS; C. Haley Walker, BA; Lori C. Jordan, MD, PhD
Includes: Supplemental Content

Importance  To our knowledge, no evidence-based guidelines are available for the best medical management of blood pressure, blood glucose levels, and temperature in pediatric patients after arterial ischemic stroke.

Objective  To determine the prevalence of abnormal blood pressure, blood glucose levels, and temperature in pediatric patients ...

Clinical Pathologic Conference 
Nathan H. Kung, MD; Robert C. Bucelli, MD, PhD; Renee B. Van Stavern, MD; Joel A. Goebel, MD; Gregory P. Van Stavern, MD
Includes: Supplemental Content

A 37-year-old man with a history of progressive bilateral sensorineural hearing loss presented to a neuro-ophthalmology clinic with an acute left homonymous hemianopsia. In this article, we discuss the clinical approach and differential diagnosis of progressive combined vision and hearing loss and guide the reader to discover the ...

Comment & Response 
Rita Cardoso, SLT, MSc; Diana Miranda, RDN; Joaquim J. Ferreira, MD, PhD

To the Editor In the article by Wills and coauthors,1 it is hypothesized that a lower body mass index (BMI) in Parkinson disease (PD) is associated with shorter survival based on the extrapolation from the association found in Huntington disease and amyotrophic lateral sclerosis. However, it is ...

Comment & Response 
Anne-Marie Wills, MD; James Boyd, MD; Adriana Pérez, PhD

In Reply We wish to clarify that our study1 was not designed to look at nutritional status in Parkinson disease. The article that we cited by Paganoni et al2 on the association between body mass index and amyotrophic lateral sclerosis found a dose-dependent effect of body ...

The ability to diagnose the pathology of neurodegenerative diseases in patients during life remains one of the holy grails of behavioral neurology. Considerable progress has been made over the past decade or so. We can now accurately predict the pathology—Alzheimer disease (AD) with plaques and tangles—in patients with ...

Original Investigation 
Noah A. Kolb, MD; A. Gordon Smith, MD; J. Robinson Singleton, MD; Susan L. Beck, PhD, APRN, AOCN; Gregory J. Stoddard, MS; Summer Brown, MD; Kathi Mooney, PhD, RN

Importance  Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic chemotherapy resulting in pain, sensory loss, and decreased quality of life. Few studies have prospectively examined the relationship between sensory neuropathy symptoms, falls, and fall-related injuries for patients receiving neurotoxic chemotherapy.

Objective  To determine ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts